Oak Ridge Investments LLC Trims Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Oak Ridge Investments LLC reduced its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 4.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 35,137 shares of the biotechnology company’s stock after selling 1,463 shares during the quarter. Oak Ridge Investments LLC’s holdings in Arrowhead Pharmaceuticals were worth $681,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also added to or reduced their stakes in the company. Fifth Third Bancorp grew its holdings in Arrowhead Pharmaceuticals by 42.5% during the 2nd quarter. Fifth Third Bancorp now owns 1,186 shares of the biotechnology company’s stock valued at $31,000 after buying an additional 354 shares in the last quarter. Headlands Technologies LLC grew its holdings in Arrowhead Pharmaceuticals by 7,696.8% during the 1st quarter. Headlands Technologies LLC now owns 2,417 shares of the biotechnology company’s stock valued at $69,000 after buying an additional 2,386 shares in the last quarter. Values First Advisors Inc. purchased a new position in shares of Arrowhead Pharmaceuticals in the third quarter valued at $52,000. Meeder Asset Management Inc. grew its holdings in shares of Arrowhead Pharmaceuticals by 4,629.2% in the second quarter. Meeder Asset Management Inc. now owns 3,405 shares of the biotechnology company’s stock valued at $88,000 after purchasing an additional 3,333 shares in the last quarter. Finally, nVerses Capital LLC purchased a new position in shares of Arrowhead Pharmaceuticals in the second quarter valued at $96,000. 62.61% of the stock is owned by hedge funds and other institutional investors.

Arrowhead Pharmaceuticals Trading Up 1.4 %

NASDAQ:ARWR opened at $19.49 on Friday. Arrowhead Pharmaceuticals, Inc. has a twelve month low of $17.05 and a twelve month high of $39.83. The company has a market cap of $2.42 billion, a price-to-earnings ratio of -4.17 and a beta of 0.95. The stock has a fifty day simple moving average of $20.64 and a 200-day simple moving average of $23.55.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($1.38) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.80). Arrowhead Pharmaceuticals’s revenue was down 100.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.96) earnings per share. As a group, equities research analysts predict that Arrowhead Pharmaceuticals, Inc. will post -4.31 EPS for the current fiscal year.

Analysts Set New Price Targets

ARWR has been the subject of a number of recent research reports. B. Riley reissued a “buy” rating and issued a $55.00 target price on shares of Arrowhead Pharmaceuticals in a report on Monday, August 12th. HC Wainwright reissued a “buy” rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a report on Friday, October 11th. Cantor Fitzgerald reissued an “overweight” rating on shares of Arrowhead Pharmaceuticals in a report on Monday, September 9th. Royal Bank of Canada restated an “outperform” rating and issued a $42.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Thursday, September 26th. Finally, StockNews.com upgraded Arrowhead Pharmaceuticals to a “sell” rating in a research report on Thursday, October 17th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $45.33.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.